Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001068 · ClinicalTrials.gov registry record · Phase 2
A Study of Disease Progression and Anti-HIV Treatments
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 20
- Study locations
NCT00001068 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 210 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00001068, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.
Conditions Studied
Interventions
- DRUG Lamivudine
Study Locations (20)
California
- USC CRS - Los Angeles
- UCLA CARE Center CRS - Los Angeles
- Stanford CRS - Palo Alto
- Ucsd, Avrc Crs - San Diego
- Ucsf Aids Crs - San Francisco
- Santa Clara Valley Med. Ctr. - San Jose
- San Mateo County AIDS Program - Stanford
- Harbor-UCLA Med. Ctr. CRS - Torrance
Illinois
- Northwestern University CRS - Chicago
- Cook County Hosp. CORE Ctr. - Chicago
- Rush Univ. Med. Ctr. ACTG CRS - Chicago
Massachusetts
- Massachusetts General Hospital ACTG CRS - Boston
- Bmc Actg Crs - Boston
Alabama
- Alabama Therapeutics CRS - Birmingham
Colorado
- University of Colorado Hospital CRS - Aurora
Florida
- Univ. of Miami AIDS CRS - Miami
Georgia
- Emory Univ. Hemophilia Program Office - Atlanta
Indiana
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Est. Completion | 1998-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001068
The ClinicalTrials.gov registry entry for NCT00001068 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (53% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Lamivudine is the first listed.
NCT00001068 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00001068 about?
NCT00001068 is a clinical study titled "A Study of Disease Progression and Anti-HIV Treatments". To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.
What is the current status of trial NCT00001068?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. Estimated completion is 1998-10.
What conditions does trial NCT00001068 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00001068?
The interventions under investigation include: Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00001068?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001068 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.